Gross Profit Analysis: Comparing Catalent, Inc. and Taro Pharmaceutical Industries Ltd.

Catalent's growth outpaces Taro's decline in gross profit.

__timestampCatalent, Inc.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 2014598600000580006000
Thursday, January 1, 2015615300000676585000
Friday, January 1, 2016587600000778966000
Sunday, January 1, 2017654600000671251000
Monday, January 1, 2018752600000463508000
Tuesday, January 1, 2019805100000445724000
Wednesday, January 1, 2020983300000399725000
Friday, January 1, 20211352000000296656000
Saturday, January 1, 20221640000000293122000
Sunday, January 1, 20231060000000268323000
Monday, January 1, 2024953000000304979000
Loading chart...

Unveiling the hidden dimensions of data

Gross Profit Trends: Catalent, Inc. vs. Taro Pharmaceutical Industries Ltd.

In the ever-evolving pharmaceutical industry, understanding financial health is crucial. This analysis compares the gross profit trends of Catalent, Inc. and Taro Pharmaceutical Industries Ltd. from 2014 to 2024. Catalent, Inc. has shown a remarkable growth trajectory, with its gross profit increasing by approximately 175% over the decade, peaking in 2022. In contrast, Taro Pharmaceutical Industries Ltd. experienced a decline of around 53% in the same period, with its highest profit recorded in 2016.

Catalent's strategic expansions and innovations have likely contributed to its robust financial performance, while Taro's challenges may stem from market competition and regulatory hurdles. This comparison highlights the dynamic nature of the pharmaceutical sector and underscores the importance of strategic planning and adaptability. As we look to the future, these trends offer valuable insights for investors and industry stakeholders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025